Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2941-2949

  Pignon, Jean Christophe ^a   Koopmansch, Benjamin ^a   Nolens, Gregory ^a   Delacroix, Laurence ^b   Waltregny, David ^a   Winkler, Rosita ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RNA POLYMERASE II; SMALL INTERFERING RNA; ERBB2 PROTEIN, HUMAN; ISOPROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 66149145906     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3760     Document Type: Article

References (48)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
2. Scher HI1 Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
3. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. MoI Cell 2007;27:380-92.
4. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral. androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008:68:4447-54.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
6. Montano X, Djamgoz MB. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 2004;571:1-8.
7. Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. Prostatic intraepithelial, neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006;27:1054-67.
8. Gregory CW, Fei X, Ponguta LA, et al. Epidermal, growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119-30.
9. Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008;283:20989-1001.
10. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
11. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival, and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-5.
12. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coacüvators: a novel pathway by induction of androgen, target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sei U S A 1999:96:5458-63.
13. Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbBl) expression in prostate cancer progression: correlation with androgen independence. Prostate 2006;66:1437-44.
14. Di LG, Tortora G, DÄrmiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
15. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (pl.85neu) protein, expression in. the natural, or treated history of prostate cancer. Clin Cancer Res 2001:7:2643-7.
16. Signoretti S, Mdntironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in. human, prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
17. Ravenna L, Lubrano C, Di SF, et al. Androgenic and antlandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 1995;26:290-8.
18. Schuurmans AL, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988;12:55-63.
19. Berger R, Lin DI, Nieto M, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006;66:5723-8.
20. Myers RB, Oelschlager DK, Hockett RD, Rogers MD, Conway-Myers BA, Grizzle WE. The effects of dihydro-testosterone on the expression of pl85(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. J Steroid Blochem Moi Biol 1996;59:441-7.
21. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human, prostatic carcinoma. Cancer Res.1983;43:1809-18.
22. Sramkoski RM, Pretlow TG, Giaconia JM, et al. A new human, prostate carcinoma cell line, 22RvI. In Vitro Cell Dev Biol Anim 1999;35:403-9.
23. van BA, Varella-Garcla M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
24. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000;60:334-41.
25. Willemsen P, Scippo ML, Kausel G, et al. Use of reporter cell lines for detection of endocrine-disrupter activity. Anal. Bioanal. Chem. 2004;378:655-63.
26. Vemimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R. Identification of HTF (HER2 transcription, factor) as an. AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003;370:323-9.
27. Delacroix L, Begon D, Chatel O, Jacken P1 Winkler R, Distal ERBB2 prumuter fragment displays spécifie transcriptional and nuclear binding activities in ERBB2 overexpresáng breast cancer cells, DNA Cell Biol 2005;24:582-94.
28. Tepper CO, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line, Cancer Res 2002;62:6606-14.
29. Ceraline J1 Cruchant MD, Erdmann E, et al. Constitutive activation of the androgen receptor by a point mutation in. the hinge region; a new mechanism for androgenrlndependent growth in prostate cancer, Int J Cancer 2004;108:152-7.
30. Dehm SM, Tindall DJ, Androgen receptor structural and functional elements: role and regulation In prostate cancer, MoI Endocrinol 2007;21:2855-63.
31. Shen HC, Coetzee GA, The androgen receptor: unlocking the secrets of its unique tronsactivatlon domain, Vltem Horm 2006;71:301-19.
32. Slmentol JA, Sar M, Lane MV, French FS, Wilson EM, Transcriptional activation and nuclear targeting signals of the human androgen receptor, J Biol Chem 1991 ¡266:510-8.
33. Quandt K, Freeh K, Karas H, Wlngender E, Werner T1 Matlnd and Matlnspector: new fast and versatile tools for detection of consensus matches In nucleotide sequence data. Nucleic Acids Res 199S23;4878-84.
34. Magee JA, Chang LW, Stormo GD, Mllbrandt J, Direct, androgen receptor-mediated regulation of the KKBPS gene via a distal enhancer element Endocrinology 2006;147:590-8.
35. Bolton EC, So AY, Chalvorapol C, Huqq CM, Ll H, Yamamoto KR Cell- and gene-speclflc regulation of primary target genes by the androgen receptor, Genes Dev 2007;21:2005-17.
36. Massle CE, Adryan B, Barbosa-Morals XL, et al. New androgen, receptor genomic targets show an Interaction with the ETSl transcription factor. EMBO Rep 2007;8:871-8.
37. Jarlwala U Prescott J, JIa L, et al, Identification of novel androgen receptor target genes In prostate cancer, Moi Cancer 2007:6:39.
38. Lu S, Jenster G, Epner DE, Androgen induction of cyclln-dependent kinase Inhibitor p21 gene: role of androgen receptor and transcription factor SpI complex, MoI Endocrinol 2000;14:753-60.
39. Lu L, Schulz H, Wolf DA, The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells, BMC Cell Biol 2002:3:22.
40. Waltregny D, Leav I, Slgnoretti S, et Bl1 Androgen-driven prostate epithelial cell proliferation and differ-entiation in vivo Involve the regulation of p27, Moi Endocrinol 2001:15:765-82.
41. Kefos B, Godlewskl J, Comean L, et al, mlcroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated In glioblastoma, Cancer Res 2008:68:3566-72.
42. Libertini SJ, Tepper CO, Rodriguez V, Asmuth DM, Kung HJ, MudryJ M, Evidence for calpaln-mediated androgen receptor cleavage as a mechanism for androgen Independence. Cancer Res 2007:67:9001-5.
43. Dehm SM, Schmidt IJ, Heemers HV, Vessella RL, Tlndall DJ, Splicing of a novel androgen receptor exon generates a constltutJvely active androgen receptor that mediates prostate cancer therapy resistance, Cancer Res 2008:68:5469-77.
44. Bergerat JP, Ceraline J, Pleiotrope functional properties of androgen receptor mutants In prostate cancer, Hum Mutat 2009:30:145-57.
45. Lapouge Q1 Erdmann E, Marclas G1 et al, Unexpected paracrine action of prostate cancer cells harboring a new class of androgen, receptor mutation-a new paradigm for cooperation among prostate tumor cells, Int J Cancer 2007:121:1238-44.
46. Lapouge G1 Marclas G, Erdmann E, et al, Specific properties of a C-termlnal truncated androgen receptor detected in hormone refractory prostate cancer, Adv Exp Med Biol 2008:617:529-34
47. Dehm SM, Tlndall DJ, Ligand-lndependent androgen receptor activity is activation functÍon-2-independent and resistant to antlandrogens In androgen refractory prostate cancer cells, J Biol Chem 2006:281:27882-93.
48. Jones HE, Barrow D, Dutkowskl CM, et al. Effect of an EGF-R selective tyrosine kinase inhibitor and an antl-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. Prostate 2001;49:38-47.